Patents Assigned to Glaxo Group Limited
  • Chemical process
    Patent number: 9273001
    Abstract: The present invention relates to a process for the preparation of umeclidinium bromide, and to processes for preparing intermediates used in the preparation of umeclidinium bromide.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: March 1, 2016
    Assignee: Glaxo Group Limited
    Inventor: John Bryce Strachan
  • Compounds
    Patent number: 9266841
    Abstract: Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in treating atherosclerosis.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 23, 2016
    Assignee: Glaxo Group Limited
    Inventors: Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, Ivan Leo Pinto, Stephen Allan Smith, Steven James Stanway
  • Apparatus for testing samples using raman radiation
    Patent number: 9261404
    Abstract: An apparatus and method using the apparatus for measuring target samples, particularly pharmaceutical products using Raman radiation. The sample is located in an aperture in a wall structure with a reflective surface on one or both of the sides of the wall structure facing respectively the excitation radiation transmitter or the Raman radiation detector. Preferably two reflective surfaces each in hemispherical shape and facing each other in a spherical arrangement are provided, with the wall structure across the diameter of the sphere.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: February 16, 2016
    Assignee: Glaxo Group Limited
    Inventors: Ralf Marbach, Jussi Tenhunen
  • Oral care compositions for combatting dental erosion
    Patent number: 9259379
    Abstract: A oral care composition comprising a triple polymer system and a source of fluoride ions for combating (i.e. helping to prevent, inhibit and/or treat) dental erosion and/or tooth wear is described. Such compositions are also of use in combating dental caries.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: February 16, 2016
    Assignee: Glaxo Group Limited
    Inventors: Ruth Corcoran-Henry, Soha Dattani, Christabel Fowler, Geeta Patel
  • Oral compositions comprising sodium dodecylbenzene sulfonate
    Patent number: 9241889
    Abstract: This invention relates to the use of sodium dodecylbenzene sulphonate (SDDBS) for helping to prevent or remove surface deposited stains from natural teeth and dental prostheses and oral care compositions comprising SDDBS for such use.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: January 26, 2016
    Assignee: Glaxo Group Limited
    Inventors: Gail Cameron Aitken, David Raymond Churchley
  • Compounds
    Patent number: 9242972
    Abstract: The present invention is directed to novel retinoid-related orphan receptor gamma (ROR?) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by ROR?.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: January 26, 2016
    Assignee: Glaxo Group Limited
    Inventors: Veronique Birault, Amanda Jennifer Campbell, Stephen Harrison, Joelle Le, Lena Shukla
  • Crystal form
    Patent number: 9227953
    Abstract: A novel crystalline form of rilapladib, and use thereof in treatment of diseases mediated by Lp-PLA2, is disclosed.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: January 5, 2016
    Assignee: Glaxo Group Limited
    Inventor: Mei-yin Lee
  • METHOD OF PRODUCING A PROTEIN
    Publication number: 20150368292
    Abstract: The present invention relates to a method of producing a recombinant protein by harvesting a microbial cell broth and adding an amount of a flocculant to achieve an effective particle size distribution. The present invention also relates to a method of clarifying a microbial harvest by adding an amount of a flocculant to achieve an effective particle size distribution.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 24, 2015
    Applicant: GLAXO GROUP LIMITED
    Inventors: Alex CHATEL, Michael HOARE, Peter KUMPALUME, Jessica Rachel MOLEK, Jason Michael RECK, Andrew David WEBER
  • POLYPEPTIDE LOADED POCA NANOPARTICLES FOR ORAL ADMINISTRATION
    Publication number: 20150342897
    Abstract: Nanoparticles comprising biologically active peptides and poly(octylcyanoacrylate) as well as related subject matter is disclosed.
    Type: Application
    Filed: May 16, 2013
    Publication date: December 3, 2015
    Applicant: Glaxo Group Limited
    Inventors: Sean Matthew Cleveland, Mark Andrew Paulik, Stefan Salomon
  • Antibodies
    Patent number: 9193784
    Abstract: Antibodies that bind human ?-amyloid peptide, methods of treating diseases or disorders characterized by elevated ?-amyloid levels or ?-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 24, 2015
    Assignee: Glaxo Group Limited
    Inventors: Stephen Anthony Burbidge, Jonathan Henry Ellis, Susannah K Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
  • Machine and method for pharmaceutical and pharmaceutical-like product assembly
    Patent number: 9187192
    Abstract: A method and apparatus for assembling a plurality of independently formed solid components is provided thereby forming a single delivery vehicle for a pharmaceutical or pharmaceutical-like product. The solid components can be held and fed to the apparatus via a plurality of magazines. Pusher rods and the like can be used for positioning each of the solid components. Where the components are connected via a bonding liquid, a sprayer is provided and compression pins or the like press the components with the bonding liquid together to form the final project. A rivet or other connection structure can also be used and driven through holes in each of the solid components to form the final product.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: November 17, 2015
    Assignee: Glaxo Group Limited
    Inventors: Thomas Bailey, Ronnie Benditt, Nigel Brewerton, Steven D. Finkelmeier, Robert Glinecke, Luigi Martini, Paul Simmons
  • Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2
    Patent number: 9174968
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: November 3, 2015
    Assignee: Glaxo Group Limited
    Inventors: Yun Jin, Zehong Wan, Qing Zhang
  • Anti-serum albumin binding variants
    Patent number: 9175071
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: November 3, 2015
    Assignee: GLAXO GROUP LIMITED
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
  • COMBINATION OF LEVOCABASTINE AND FLUTICASONE FUROATE FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC CONDITIONS
    Publication number: 20150297614
    Abstract: The present invention relates to pharmaceutical formulations comprising an anti-inflammatory glucocorticoid compound of the androstane series and levocabastine, an H1 antagonist/anti-allergic, and also relates to therapeutic uses thereof, particularly for the treatment of inflammatory and allergic conditions, specifically rhinitis.
    Type: Application
    Filed: December 13, 2013
    Publication date: October 22, 2015
    Applicant: Glaxo Group Limited
    Inventors: Diane Michele Ignar, Daren Scott Levin
  • MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES
    Publication number: 20150299121
    Abstract: The present invention relates to novel retinoid-related orphan receptor gamma (ROR?) modulators and their use in the treatment of diseases mediated by ROR?.
    Type: Application
    Filed: December 5, 2013
    Publication date: October 22, 2015
    Applicant: Glaxo Group Limited
    Inventors: Fangbin HAN, Hui LEI, Xichen LIN, Qinghua MENG, Yonghui WANG
  • Process for providing a quantity of a particulate material, product and apparatus
    Patent number: 9161884
    Abstract: A process for providing a predetermined quantity of a particulate material in which the particulate material is deposited on a defined area of a sticky surface of a substrate. The process is suitable for deposition of particulate drug material on a substrate such as a strip form substrate which can then be compacted to provide a delivery device for delivering the predetermined quantity of the particulate material. Such a delivery device, and an apparatus to perform the process, comprise further aspects of the invention.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: October 20, 2015
    Assignee: Glaxo Group Limited
    Inventors: Stephen Barlow, Howard Biddle, Roderick Haines, Keith Smith
  • Production methods
    Patent number: 9163249
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: October 20, 2015
    Assignee: Glaxo Group Limited
    Inventors: Mark Uden, Ekaterini Kotsopoulou
  • Pyrazole compounds acting against allergic, immune and inflammatory conditions
    Patent number: 9156791
    Abstract: The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: October 13, 2015
    Assignee: Glaxo Group Limited
    Inventors: Anthony William James Cooper, Paul Martin Gore, David House
  • Toothbrush
    Patent number: D747882
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: January 26, 2016
    Assignee: Glaxo Group Limited
    Inventors: Marcus Blachford, Alex Brian, Charles Drury, Rhodri Jones, Peter Kay, William Knight
  • Travel cap
    Patent number: D748398
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: February 2, 2016
    Assignee: Glaxo Group Limited
    Inventors: Marcus Blachford, Alex Brian, Charles Drury, Rhodri Jones, Peter Kay, William Knight